Polymorphs and salts
US-9353098-B2 · May 31, 2016 · US
Novel Polymorphs and Salts
US2016237073A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016237073-A1 |
| Application number | US-201615138277-A |
| Country | US |
| Kind code | A1 |
| Filing date | Apr 26, 2016 |
| Priority date | Sep 8, 2010 |
| Publication date | Aug 18, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
First claim
Opening claim text (preview).
What is claimed is: 1 - 15 . (canceled) 16 . A salt of N-[5-[4-(5-{[(2R,6S)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1H-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide which is selected from the group consisting of from sodium, tosylate, maleate, hemi pamoate, hemi naphthalenedisulfonate, mesitylenesulfonate, hemi biphenyldisulfonate, 2-naphthalenesulfonate (napsylate), hemi cinnamate, hemi sebacate, hemi pyromellitate and hemi benzenediacrylate. 17 . A pharmaceutical composition comprising a salt according to claim 16 and one or more pharmaceutically acceptable excipients.
Assignees
Inventors
Classifications
- C07D413/14Primary
containing three or more hetero rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016237073A1 cover?
- The present invention is directed to novel polymorphs and salts of a compound which is an inhibitor of kinase activity.
- Who is the assignee on this patent?
- Glaxo Group Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D413/14. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Aug 18 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).